Since the KISIMA-Mash2 vaccine promoted some immunogenicity in Apc+/Min-FCCC mice, a larger study was conducted to determine the ability of the vaccine to prevent colon tumor formation. This evidence concerns the gene ASCL2 and colonic neoplasm.